Rocket Lab Announces First Quarter 2026 Financial Results: Surpasses All Guidance Metrics Including Revenue, Margin, And Adjusted EBITDA Posts Record $200M Quarterly Revenue And Over $2.2B Backlog Guides Another Record Revenue
| ROCKET LAB CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (unaudited; in thousands, except share and per share data) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Revenues: | |||||||
| Product revenues | $ | 127,488 | $ | 80,804 | |||
| Service revenues | 72,860 | 41,765 | |||||
| Total revenues | 200,348 | 122,569 | |||||
| Cost of revenues: | |||||||
| Cost of product revenues | 81,084 | 53,869 | |||||
| Cost of service revenues | 42,771 | 33,453 | |||||
| Total cost of revenues | 123,855 | 87,322 | |||||
| Gross profit | 76,493 | 35,247 | |||||
| Operating expenses: | |||||||
| Research and development, net | 80,513 | 55,109 | |||||
| Selling, general and administrative | 51,949 | 39,326 | |||||
| Total operating expenses | 132,462 | 94,435 | |||||
| Operating loss | (55,969 | ) | (59,188 | ) | |||
| Other income (expense): | |||||||
| Interest expense | (1,274 | ) | (6,795 | ) | |||
| Interest income | 10,149 | 4,209 | |||||
| Gain (loss) on foreign exchange | 156 | (134 | ) | ||||
| Other income, net | 124 | 479 | |||||
| Total other income (expense), net | 9,155 | (2,241 | ) | ||||
| Loss before income taxes | (46,814 | ) | (61,429 | ) | |||
| Benefit for income taxes | 1,792 | 813 | |||||
| Net loss | $ | (45,022 | ) | $ | (60,616 | ) | |
| Net loss per share attributable to Rocket Lab Corporation: | |||||||
| Basic and diluted | $ | (0.07 | ) | $ | (0.12 | ) | |
| Weighted-average common shares outstanding: | |||||||
| Basic and diluted | 605,434,642 | 505,614,185 |
| ROCKET LAB CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2026 AND DECEMBER 31, 2025 (unaudited; in thousands, except share and per share values) | |||||||
| March 31, 2026 (unaudited) | December 31, 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 1,205,499 | $ | 828,660 | |||
| Marketable securities, current | 177,852 | 187,917 | |||||
| Accounts receivable, net | 74,955 | 39,001 | |||||
| Contract assets | 75,036 | 61,606 | |||||
| Inventories | 183,146 | 158,407 | |||||
| Prepaids and other current assets | 83,874 | 89,953 | |||||
| Total current assets | 1,800,362 | 1,365,544 | |||||
| Non-current assets: | |||||||
| Property, plant and equipment, net | 343,988 | 319,473 | |||||
| Intangible assets, net | 220,567 | 224,746 | |||||
| Goodwill | 208,738 | 205,750 | |||||
| Right-of-use assets - operating leases | 90,933 | 90,371 | |||||
| Right-of-use assets - finance leases | 13,767 | 13,895 | |||||
| Marketable securities, non-current | 93,494 | 82,247 | |||||
| Restricted cash | 5,524 | 4,885 | |||||
| Deferred income tax assets, net | 849 | 1,895 | |||||
| Other non-current assets | 41,719 | 15,672 | |||||
| Total assets | $ | 2,819,941 | $ | 2,324,478 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities: | |||||||
| Trade payables | $ | 63,112 | $ | 72,699 | |||
| Accrued expenses | 33,546 | 19,299 | |||||
| Employee benefits payable | 40,720 | 25,803 | |||||
| Contract liabilities | 241,412 | 195,438 | |||||
| Other current liabilities | 23,555 | 21,237 | |||||
| Total current liabilities | 402,345 | 334,476 | |||||
| Non-current liabilities: | |||||||
| Convertible senior notes, net | 36,869 | 152,395 | |||||
| Long-term borrowings, net | 1,716 | 1,716 | |||||
| Non-current operating lease liabilities | 85,517 | 85,191 | |||||
| Non-current finance lease liabilities | 14,568 | 14,653 | |||||
| Deferred income tax liabilities | 1,352 | 1,241 | |||||
| Other non-current liabilities | 13,207 | 12,952 | |||||
| Total liabilities | 555,574 | 602,624 | |||||
| COMMITMENTS AND CONTINGENCIES | |||||||
| Stockholders' equity: | |||||||
| Preferred stock, $0.0001 par value; authorized shares: 100,000,000; issued and outstanding shares: 45,951,250 at March 31, 2026 and December 31, 2025 | 5 | 5 | |||||
| Common stock, $0.0001 par value; authorized shares: 2,500,000,000; issued shares: 621,718,750 and 589,525,802 at March 31, 2026 and December 31, 2025, respectively; outstanding shares: 575,767,500 and 543,574,552 at March 31, 2026 and December 31, 2025, respectively | 58 | 54 | |||||
| Treasury stock, at cost; shares: 45,951,250 at March 31, 2026 and December 31, 2025 | - | - | |||||
| Additional paid-in capital | 3,324,206 | 2,735,669 | |||||
| Accumulated deficit | (1,056,932 | ) | (1,011,910 | ) | |||
| Accumulated other comprehensive loss | (2,970 | ) | (1,964 | ) | |||
| Total stockholders' equity | 2,264,367 | 1,721,854 | |||||
| Total liabilities and stockholders' equity | $ | 2,819,941 | $ | 2,324,478 |
| ROCKET LAB CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (unaudited; in thousands) | |||||||
| For the Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
| Net loss | $ | (45,022 | ) | $ | (60,616 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization | 14,990 | 8,707 | |||||
| Stock-based compensation expense | 28,116 | 19,234 | |||||
| (Gain) loss on disposal of assets | (409 | ) | 13 | ||||
| Amortization of debt issuance costs and discount | 133 | 831 | |||||
| Noncash lease expense | 2,797 | 1,519 | |||||
| Change in the fair value of contingent consideration | 187 | - | |||||
| Accretion of marketable securities purchased at a discount | (458 | ) | (561 | ) | |||
| Deferred income taxes | 1,155 | (585 | ) | ||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable, net | (35,662 | ) | (2,974 | ) | |||
| Contract assets | (13,434 | ) | 2,165 | ||||
| Inventories | (24,571 | ) | (6,308 | ) | |||
| Prepaids and other current assets | 4,081 | (9,617 | ) | ||||
| Other non-current assets | (26,098 | ) | 1,571 | ||||
| Trade payables | (8,161 | ) | 9,779 | ||||
| Accrued expenses | 10,825 | (2,712 | ) | ||||
| Employee benefits payables | 1,309 | (253 | ) | ||||
| Contract liabilities | 45,753 | (9,294 | ) | ||||
| Other current liabilities | (2,941 | ) | (3,699 | ) | |||
| Non-current lease liabilities | (2,993 | ) | (1,670 | ) | |||
| Other non-current liabilities | 71 | 245 | |||||
| Net cash used in operating activities | (50,332 | ) | (54,225 | ) | |||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
| Purchases of property, equipment and software | (27,065 | ) | (28,677 | ) | |||
| Proceeds on disposal of assets | 715 | 16 | |||||
| Cash paid for business combinations, net of acquired cash | (8,021 | ) | - | ||||
| Purchases of marketable securities | (91,328 | ) | (84,639 | ) | |||
| Maturities of marketable securities | 89,979 | 84,699 | |||||
| Net cash used in investing activities | (35,720 | ) | (28,601 | ) | |||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
| Proceeds from ATM Equity Offerings | 450,347 | 92,806 | |||||
| Issuance costs related to ATM Equity Offerings | (4,740 | ) | (2,088 | ) | |||
| Proceeds from the exercise of stock options | 1,081 | 48 | |||||
| Proceeds from Employee Stock Purchase Plan | 4,189 | 2,237 | |||||
| Proceeds from sale of employees restricted stock units to cover taxes | 52,337 | 17,310 | |||||
| Minimum tax withholding paid on behalf of employees for restricted stock units | (39,848 | ) | (16,577 | ) | |||
| Proceeds from secured term loans | - | 25,000 | |||||
| Repayments on secured term loan | - | (2,894 | ) | ||||
| Payment of debt issuance costs | - | (278 | ) | ||||
| Finance lease principal payments | (73 | ) | (61 | ) | |||
| Net cash provided by financing activities | 463,293 | 115,503 | |||||
| Effect of exchange rate changes on cash and cash equivalents | 237 | 272 | |||||
| Net increase in cash and cash equivalents and restricted cash | 377,478 | 32,949 | |||||
| Cash and cash equivalents, and restricted cash, beginning of period | 833,545 | 275,302 | |||||
| Cash and cash equivalents, and restricted cash, end of period | $ | 1,211,023 | $ | 308,251 |
| ROCKET LAB CORPORATION AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (unaudited; in thousands) |
The tables provided below reconcile the non-GAAP financial measures Adjusted EBITDA, Non-GAAP gross profit, Non-GAAP research and development, net, Non-GAAP selling, general and administrative, Non-GAAP operating expenses, Non-GAAP operating loss and Non-GAAP total other income (expense), net with the most directly comparable GAAP financial measures. See above for additional information on the use of these non-GAAP financial measures.
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| NET LOSS | $ | (45,022 | ) | $ | (60,616 | ) | |
| Depreciation | 7,514 | 5,689 | |||||
| Amortization | 7,476 | 3,018 | |||||
| Stock-based compensation expense | 28,116 | 19,234 | |||||
| Transaction costs | 1,668 | 1,378 | |||||
| Interest expense | 1,274 | 6,795 | |||||
| Interest income | (10,149 | ) | (4,209 | ) | |||
| Change in fair value of contingent consideration | 187 | - | |||||
| Benefit for income taxes | (1,792 | ) | (813 | ) | |||
| (Gain) loss on foreign exchange | (156 | ) | 134 | ||||
| Accretion of marketable securities and cash equivalents purchased at a discount | (458 | ) | (585 | ) | |||
| (Gain) loss on disposal of assets | (409 | ) | 13 | ||||
| ADJUSTED EBITDA | $ | (11,751 | ) | $ | (29,962 | ) |
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| GAAP Gross profit | $ | 76,493 | $ | 35,247 | |||
| Stock-based compensation | 3,506 | 3,920 | |||||
| Amortization of purchased intangibles and favorable lease | 6,094 | 1,823 | |||||
| Non-GAAP Gross profit | $ | 86,093 | $ | 40,990 | |||
| Non-GAAP Gross margin | 43.0 | % | 33.4 | % | |||
| GAAP Research and development, net | $ | 80,513 | $ | 55,109 | |||
| Stock-based compensation | (5,846 | ) | (4,894 | ) | |||
| Amortization of purchased intangibles and favorable lease | - | (165 | ) | ||||
| Non-GAAP Research and development, net | $ | 74,667 | $ | 50,050 | |||
| GAAP Selling, general and administrative | $ | 51,949 | $ | 39,326 | |||
| Stock-based compensation | (18,764 | ) | (10,420 | ) | |||
| Amortization of purchased intangibles and favorable lease | (1,105 | ) | (776 | ) | |||
| Transaction costs | (1,668 | ) | (1,378 | ) | |||
| Non-GAAP Selling, general and administrative | $ | 30,412 | $ | 26,752 | |||
| GAAP Operating expenses | $ | 132,462 | $ | 94,435 | |||
| Stock-based compensation | (24,610 | ) | (15,314 | ) | |||
| Amortization of purchased intangibles and favorable lease | (1,105 | ) | (941 | ) | |||
| Transaction costs | (1,668 | ) | (1,378 | ) | |||
| Non-GAAP Operating expenses | $ | 105,079 | $ | 76,802 | |||
| GAAP Operating loss | $ | (55,969 | ) | $ | (59,188 | ) | |
| Total non-GAAP adjustments | 36,983 | 23,376 | |||||
| Non-GAAP Operating loss | $ | (18,986 | ) | $ | (35,812 | ) | |
| GAAP Total other income (expense), net | $ | 9,155 | $ | (2,241 | ) | ||
| (Gain) loss on foreign exchange | (156 | ) | 134 | ||||
| (Gain) loss on disposal of assets | (409 | ) | 13 | ||||
| Change in fair value of contingent consideration | 187 | - | |||||
| Non-GAAP Total other income (expense), net | $ | 8,777 | $ | (2,094 | ) |
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment